Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study

The Lancet - Tập 389 Số 10071 - Trang 815-822 - 2017
Hashim U. Ahmed1,2, Ahmed El‐Shater Bosaily1,2, Louise Brown3, Rhian Gabe4, Richard Kaplan3, Mahesh Parmar3, Yolanda Collaço‐Moraes3, Katie Ward3, Richard G. Hindley5, Alex Freeman6, Alex Kirkham7, Robert Oldroyd8, Chris Parker9, Mark Emberton1,2
1 Department of Urology, UCLH NHS Foundation Trust, London, UK
2Division of Surgery and Interventional Science, Faculty of Medical Sciences, University College London, London, UK
3MRC Clinical Trials Unit at UCL, London, UK
4Hull York Medical School and Department of Health Sciences, University of York, UK
5Department of Urology, Hampshire Hospitals NHS Foundation Trust, UK
6Department of Histopathology, UCLH NHS Foundation Trust, London, UK
7Department of Radiology, UCLH NHS Foundation Trust, London, UK
8Public and patient representative, Nottingham, UK
9Department of Academic Urology, Royal Marsden Hospital, Sutton, UK

Tóm tắt

Từ khóa


Tài liệu tham khảo

Caverly, 2016, Presentation of Benefits and Harms in US Cancer Screening and Prevention Guidelines: Systematic Review, J Natl Cancer Inst, 108, djv436, 10.1093/jnci/djv436

Abraham, 2015, Patterns of repeat prostate biopsy in contemporary clinical practice, J Urol, 193, 1178, 10.1016/j.juro.2014.10.084

Loeb, 2013, Systematic review of complications of prostate biopsy, Eur Urol, 64, 876, 10.1016/j.eururo.2013.05.049

Turkbey, 2016, Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer, C A Cancer J Clin, 66, 326, 10.3322/caac.21333

Mowatt, 2013, The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation, Health Technol Assess, 17, vii, 10.3310/hta17200

Valerio, 2015, Methodological considerations in assessing the utility of imaging in early prostate cancer, Curr Opin Urol, 25, 536, 10.1097/MOU.0000000000000219

Bossuyt, 2006, Comparative accuracy: assessing new tests against existing diagnostic pathways, BMJ, 332, 1089, 10.1136/bmj.332.7549.1089

El-Shater Bosaily, 2015, PROMIS–Prostate MR imaging study: a paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer, Contemp Clin Trials, 42, 26, 10.1016/j.cct.2015.02.008

Ahmed, 2009, Is it time to consider a role for MRI before prostate biopsy?, Nat Rev Clin Oncol, 6, 197, 10.1038/nrclinonc.2009.18

Phillips

Bossuyt, 2015, STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies, BMJ, 351, h5527, 10.1136/bmj.h5527

Dickinson, 2011, Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting, Eur Urol, 59, 477, 10.1016/j.eururo.2010.12.009

Barentsz, 2012, ESUR prostate MR guidelines 2012, Eur Radiol, 22, 746, 10.1007/s00330-011-2377-y

Rosenkrantz, 2013, Comparison of interreader reproducibility of the prostate imaging reporting and data system and likert scales for evaluation of multiparametric prostate MRI, Am J Roentgenol, 201, W612, 10.2214/AJR.12.10173

Rastinehad, 2015, Comparison of multiparametric MRI scoring systems and the impact on cancer detection in patients undergoing MR US fusion guided prostate biopsies, PLoS One, 10, e0143404, 10.1371/journal.pone.0143404

Hu, 2012, A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)-biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy, BJU Int, 110, 812, 10.1111/j.1464-410X.2012.10933.x

Valerio, 2016, Transperineal template prostate-mapping biopsies: an evaluation of different protocols in the detection of clinically significant prostate cancer, BJU Int, 118, 384, 10.1111/bju.13306

Heidenreich, 2011, EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease, Eur Urol, 59, 61, 10.1016/j.eururo.2010.10.039

Stark, 2009, Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?, J Clin Oncol, 27, 3459, 10.1200/JCO.2008.20.4669

Kepner, 2010, Transperineal biopsy: analysis of a uniform core sampling pattern that yields data on tumor volume limits in negative biopsies, Theor Biol Med Model, 7, 23, 10.1186/1742-4682-7-23

Wolters, 2011, A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a random screening trial, J Urol, 185, 121, 10.1016/j.juro.2010.08.082

Stamey, 1993, Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer, Cancer, 71, 933, 10.1002/1097-0142(19930201)71:3+<933::AID-CNCR2820711408>3.0.CO;2-L

Ahmed, 2011, Characterizing clinically significant prostate cancer using template prostate mapping biopsy, J Urol, 186, 458, 10.1016/j.juro.2011.03.147

Leisenring, 2000, Comparisons of predictive values of binary medical diagnostic tests for paired designs, Biometrics, 56, 345, 10.1111/j.0006-341X.2000.00345.x

Wang, 2006, Comparison of predictive values of two diagnostic tests from the same sample of subjects using weighted least squares, Stat Med, 25, 2215, 10.1002/sim.2332

Radtke, 2015, Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance, J Urol, 193, 87, 10.1016/j.juro.2014.07.098

Kasivisvanathan, 2013, Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer, J Urol, 189, 860, 10.1016/j.juro.2012.10.009

de Groot, 2011, Verification problems in diagnostic accuracy studies: consequences and solutions, BMJ, 343, d4770, 10.1136/bmj.d4770

de Rooij, 2014, Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis, Am J Roentgenol, 202, 343, 10.2214/AJR.13.11046

Fütterer, 2015, Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature, Eur Urol, 68, 1045, 10.1016/j.eururo.2015.01.013

Thompson, 2014, Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study, J Urol, 192, 67, 10.1016/j.juro.2014.01.014

Thompson, 2014, Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study, J Urol, 192, 67, 10.1016/j.juro.2014.01.014

Thompson, 2016, The Diagnostic Performance of Multiparametric Magnetic Resonance Imaging to Detect Significant Prostate Cancer, J Urol, 195, 1428, 10.1016/j.juro.2015.10.140

El-Shater Bosaily, 2014, Re: Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study, J Urol, 192, 67, 10.1016/j.juro.2014.01.014

Crawford, 2013, Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens, Prostate, 73, 778, 10.1002/pros.22622

Bittner, 2015, Diagnostic performance of initial transperineal template-guided mapping biopsy of the prostate gland, Am J Clin Oncol, 38, 300, 10.1097/COC.0b013e31829a2954

Valerio, 2016, The prevalence of clinically significant prostate cancer according to commonly used histological thresholds in men undergoing template prostate mapping biopsies, J Urol, 195, 1403, 10.1016/j.juro.2015.11.047

Lane, 2014, Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial, Lancet Oncol, 15, 1109, 10.1016/S1470-2045(14)70361-4

Grönberg, 2015, Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study, Lancet Oncol, 16, 1667, 10.1016/S1470-2045(15)00361-7